The article focuses on several approaches of the dipeptidyl peptidase-4 inhibitors. It mentions that diabetes is a cardiovascular (CV) risk equivalent with diagnosis conveying mortality risk with history of myocardial infarction (MI) or stroke. It also highlights studies related to durability of the glucose-lowering effect with DPP-4i.